Xavier Durando
Impact in
- Molecular Medicine top 2%
- Curcumin's Biomedical Applications
- Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer, Hypoxia, and Metabolism
Papers in
- Oncology 85
- Cancer Treatment and Pharmacology 27
- HER2/EGFR in Cancer Research 15
- Cancer Immunotherapy and Biomarkers 13
- Cancer Risks and Factors 11
-
- Breast Cancer Treatment Studies 35
- Co-authors
- P. Chollet (52 shared papers)Catherine Abrial (52 shared papers)Émilie Thivat (51 shared papers)Marie‐Ange Mouret‐Reynier (34 shared papers)E. Planchat (15 shared papers)Frédérique Penault‐Llorca (26 shared papers)Marianne Leheurteur (11 shared papers)Pierre Gimbergues (21 shared papers)
- Journals
- Journal of Clinical Oncology (18 papers)BMC Cancer (11 papers)Annals of Oncology (8 papers)Oncology (7 papers)Cancer Investigation (6 papers)
- Partner nations
- FranceItalyUnited States
In The Last Decade
Xavier Durando
130 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 112
- Molecular Medicine 287
- Cancer Research 774
- Oncology 1.0k
- Genetics 263
- Biotechnology 187
Countries citing papers authored by Xavier Durando
This map shows the geographic impact of Xavier Durando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Durando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Durando more than expected).
Fields of papers citing papers by Xavier Durando
This network shows the impact of papers produced by Xavier Durando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Durando. The network helps show where Xavier Durando may publish in the future.
Co-authors
The 25 scholars most cited alongside Xavier Durando, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 140 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 297 | |
| 2 | 2003 | 167 | |
| 3 | 2016 | 112 | |
| 4 | 2012 | 111 | |
| 5 | 2010 | 92 | |
| 6 | 2014 | 92 | |
| 7 | 2007 | 76 | |
| 8 | 2011 | 71 | |
| 9 | 2014 | 69 | |
| 10 | 2015 | 68 | |
| 11 | 2008 | 68 | |
| 12 | 2012 | 68 | |
| 13 | 2016 | 61 | |
| 14 | Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma. | 2009 | 54 |
| 15 | 2010 | 53 | |
| 16 | 2008 | 51 | |
| 17 | 2008 | 51 | |
| 18 | 2007 | 47 | |
| 19 | 2011 | 47 | |
| 20 | 2008 | 47 |
About Xavier Durando
Xavier Durando is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Genetics, having authored 140 papers that have together received 2.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (35 papers), Cancer Treatment and Pharmacology (27 papers), Glioma Diagnosis and Treatment (22 papers), Brain Metastases and Treatment (18 papers), HER2/EGFR in Cancer Research (15 papers), Cancer Immunotherapy and Biomarkers (13 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Risks and Factors (11 papers). The work is most often cited by research in Molecular Medicine (287 citations), Cancer Research (774 citations), Oncology (1.0k citations), Genetics (263 citations) and Biotechnology (187 citations). Xavier Durando has collaborated with scholars based in France, Italy and United States. Frequent co-authors include P. Chollet, Catherine Abrial, Émilie Thivat, Marie‐Ange Mouret‐Reynier, E. Planchat, Frédérique Penault‐Llorca, Marianne Leheurteur, Pierre Gimbergues, Émilie Gadéa and Fabrice Kwiatkowski. Their work appears in journals such as Journal of Clinical Oncology, BMC Cancer, Annals of Oncology, Oncology and Cancer Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.